Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.".
Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.".